Leadership Changes - Glen French has been reappointed as President and Chief Executive Officer of Pulmonx Corporation, effective immediately [1][3] - Derrick Sung has been appointed as Chief Operating Officer and Chief Financial Officer, effective November 3, 2025 [1][3] - Steve Williamson and Mehul Joshi have resigned from their roles but will serve in advisory capacities until December 1, 2025 [1][3] Financial Performance - Preliminary revenue for the third quarter of 2025 is anticipated to be approximately $21.5 million [4] - The company plans to provide further details on its third quarter results during a conference call rescheduled for November 12, 2025 [4][6] Company Overview - Pulmonx Corporation is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD) [9] - The company's Zephyr Endobronchial Valve is a standard treatment option for patients with severe emphysema and is commercially available in over 25 countries [9]

Core Insights - Pulmonx Corporation will release its financial results for Q3 2025 on October 29, 2025, after market close, followed by a conference call at 1:30 p.m. PT / 4:30 p.m. ET [1] Company Overview - Pulmonx Corporation is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD) [3] - The company's key products include the Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX™ Platform, and StratX Lung Analysis Reports, aimed at treating patients with severe emphysema/COPD [3] - The Zephyr Valve has received FDA pre-market approval as a "breakthrough device" and is available in over 25 countries, recognized in global treatment guidelines as a standard care option for improving patient outcomes [3]

Company Overview - Pulmonx Corporation is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD) [2] - The company's key products include the Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX™ Platform, and StratX Lung Analysis Reports, which are designed for patients with severe emphysema/COPD [2] - The Zephyr Valve has received FDA pre-market approval as a "breakthrough device" and is commercially available in over 25 countries, recognized as a standard treatment option for improving patient outcomes [2] Upcoming Investor Conferences - Pulmonx management will present at the Wells Fargo Healthcare Conference on September 4 at 1:30 pm PT/4:30 pm ET in Boston, MA, featuring a fireside chat and 1x1 meetings [1] - The company will also participate in the Lake Street Best Ideas Growth (BIG9) Conference on September 11 in New York, NY, focusing on 1x1 meetings [1] - A live and archived webcast of the fireside chat will be accessible on the "Investors" section of the Pulmonx website [1]